Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
PCA3 test for prostate cancer: Data presented June 1 at the American Urological Association annual meeting shows Gen-Probe's Progensa urine-based molecular test is significantly more specific than prostate specific antigen in detecting prostate cancer. A multi-practice, community-urologist-based clinical trial evaluated PCA3 in 1,994 urine samples from men with elevated serum PSA and/or an abnormal digital rectal exam, of which 1,946 had enough prostatic cells for PCA3 testing. Researchers found that 816 patients (42%) had prostate cancer, and another 219 (11%) had high-grade prostatic intraepithelial neoplasia and/or atypical small acinar proliferation suspicious for cancer. The results concluded PCA3 has an odds ratio of 3.4 for predicting prostate cancer versus 1.7 for PSA. PCA3 had a specificity of 78% and sensitivity of 49%, versus 21% and 87%, respectively, for PSA. The PCA3 gene is overexpressed in more than 90% of prostate cancers. The assay has CE-mark approval in Europe; Gen-Probe initiated a U.S. clinical trial in August 2009 and plans to submit a PMA application later this year
You may also be interested in...
St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity
With the publication of the CHAMPION clinical trial results, CardioMEMS and its suitor St. Jude Medical took another step toward leading the pack in what they say is a multi-billion dollar market opportunity in hemodynamic heart failure monitoring.
St. Jude: CardioMEMS’ Heart Failure Data Reflects Major Opportunity
With the publication of the CHAMPION clinical trial results, CardioMEMS and its suitor St. Jude Medical took another step toward leading the pack in what they say is a multi-billion dollar market opportunity in hemodynamic heart failure monitoring.
At CMS Town Hall, Firms Pitch New Tech's Impact On Reducing Hospital Stays
Three companies seeking Medicare new-technology add-on payments for 2012 argued last week that reimbursing more for their products up front could help lower overall health care costs.